A commentary piece in the biotech investing ecosystem argued that scientific breakthroughs are not the limiting factor for most new companies; operational execution—GMP production, quality systems, regulatory review, and supply chain launch—determines whether therapies become scalable products. The article emphasizes that operational talent and process discipline can’t be built overnight, and investors increasingly weigh execution capability alongside scientific novelty.